Abstract:This study reports on biallelic homozygous and monoallelic de novo variants in SLITRK3 in three unrelated families presenting with epileptic encephalopathy associated with a broad neurological involvement characterized by microcephaly, intellectual disability, seizures, and global developmental delay. SLITRK3 encodes for a transmembrane protein that is involved in controlling neurite outgrowth and inhibitory synapse development and that has an important role in brain function and neurological diseases. Using primary cultures of hippocampal neurons carrying patients' SLITRK3 variants and in combination with electrophysiology, we demonstrate that recessive variants are loss-of-function alleles. Immunostaining experiments in HEK-293 cells showed that human variants C566R and E606X change SLITRK3 protein expression patterns on the cell surface, resulting in highly accumulating defective proteins in the Golgi apparatus. By analyzing the development and phenotype of SLITRK3 KO ( SLITRK3 –/– ) mice, the study shows evidence of enhanced susceptibility to pentylenetetrazole-induced seizure with the appearance of spontaneous epileptiform EEG as well as developmental deficits such as higher motor activities and reduced parvalbumin interneurons. Taken together, the results exhibit impaired development of the peripheral and central nervous system and support a conserved role of this transmembrane protein in neurological function. The study delineates an emerging spectrum of human core synaptopathies caused by variants in genes that encode SLITRK proteins and essential regulatory components of the synaptic machinery. The hallmark of these disorders is impaired postsynaptic neurotransmission at nerve terminals; an impaired neurotransmission resulting in a wide array of (often overlapping) clinical features, including neurodevelopmental impairment, weakness, seizures, and abnormal movements. The genetic synaptopathy caused by SLITRK3 mutations highlights the key roles of this gene in human brain development and function.

Insight into the Association between Slitrk Protein and Neurodevelopmental and Neuropsychiatric Conditions

SLITRK2 variants associated with neurodevelopmental disorders impair excitatory synaptic function and cognition in mice

Loss-of-function variant in the LRR domain of SLITRK2 implicated in a neurodevelopmental disorder

A Review on the Current Neuroligin Mouse Models.

Human mutations in SLITRK3 implicated in GABAergic synapse development in mice

SLITRK1-mediated noradrenergic projection suppression in the neonatal prefrontal cortex

Slitrk5 Mediates BDNF-Dependent TrkB Receptor Trafficking and Signaling

Molecular Insights into the Role of Pathogenic Nssnps in GRIN2B Gene Provoking Neurodevelopmental Disorders

Slitrk4 is required for the development of inhibitory neurons in the fear memory circuit of the lateral amygdala

Variants in LRRC7 lead to intellectual disability, autism, aggression and abnormal eating behaviors

The lemur tail kinase family in neuronal function and disfunction in neurodegenerative diseases

Genetic insights and neurobiological implications from NRXN1 in neuropsychiatric disorders

Effect of Schizophrenia linked DRD2 gene mutations and correlation of social behavior with biochemical changes in a post-weaning isolated mouse model

Changes in SLITRK1 Level in the Amygdala Mediate Chronic Neuropathic Pain-Induced Anxio-Depressive Behaviors in Mice

Roles of neuroligins in central nervous system development: focus on glial neuroligins and neuron neuroligins

Roles of PI3K/AKT/GSK3 Pathway Involved in Psychiatric Illnesses

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology

Zmiz1 is a novel regulator of brain development associated with autism and intellectual disability

Association of SHANK Family with Neuropsychiatric Disorders: An Update on Genetic and Animal Model Discoveries

Brain-specific deletion of GIT1 impairs cognition and alters phosphorylation of synaptic protein networks implicated in schizophrenia susceptibility

Synaptic Protein DLG2 Controls Neurogenic Transcriptional Programs Disrupted in Schizophrenia and Related Disorders